(RTTNews) - Actinium Pharmaceuticals, Inc. (ATNM), a clinical-stage biopharmaceutical company developing targeted radiotherapies for cancer, said Thursday it has appointed Matt David as chief financial officer.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.